(CercleFinance.com) – Biophytis rose on the Paris Stock Exchange on Monday after announcing its intention to explore the potential of Sarconeos, its small molecule, in the treatment of viral respiratory failure.
The biotechnology company announced this morning the signing of a partnership with the University of Liège with a view to carrying out various preclinical research work, particularly in the treatment of respiratory failure caused by the influenza virus.
Under the terms of the agreement, the university’s animal pathology research laboratory will conduct a series of experiments aimed at establishing the therapeutic potential of Sarconeos (BIO101) in an experimental mouse model of infection caused by the virus. influenza, which may cause respiratory failure and death in the elderly.
This work is a continuation of a collaboration started in 2020 which made it possible to establish proof of the effectiveness and original mode of action of Sarconeos in Covid.
Listed on the Paris Stock Exchange, Biophytis shares rose 5% on Monday on the Paris Stock Exchange after these announcements.